Background Cediranib (AZD2171), an oral pan-vascular endothelial growth factor (VEGF) inhibitor, was evaluated in this phase I study to determine its toxicity profile, doselimiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics in children and adolescents with recurrent or refractory primary central nervous system (CNS) tumors. Methods Children and adolescents <22 years were enrolled into one of two strata: stratum I-those not receiving enzyme-inducing anticonvulsant drugs (EIACD) and stratum II-those receiving EIACDs. Dose-level selection was based on the continual reassessment method (CRM).
Results Thirty-six eligible patients with median age of 12.7 years (range, 5.4-21.7 years) in stratum I (24 males) and 12 patients (7 males) in stratum II with median age of 13.4 years (range, 8.9-19.5 years) were initially assessed over a 4-week DLT evaluation period, modified to 6 weeks during the study. An MTD of 32 mg/m 2 /day was declared; however, excessive toxicities (transaminitis, proteinuria, diarrhea, hemorrhage, palmer-planter syndrome, reversible posterior leukoencephalopathy) in the expansion cohort treated at this dose suggested that it might not be tolerated over a longer time period. An expansion cohort at 20 mg/m 2 /day also demonstrated poor longer-term tolerability. Diffusion and perfusion MRI and PET imaging variables as well as biomarker analysis were performed and correlated with outcome. At 20 mg/m 2 / Electronic supplementary material The online version of this article (doi:10.1007/s00381-015-2812-5) contains supplementary material, which is available to authorized users. day, the median plasma area under the concentration-time curve at steady state was lower than that observed in adults at similar dosages. Conclusions While the MTD of once daily oral cediranib in children with recurrent or progressive CNS tumors was initially defined as 32 mg/m Introduction Cediranib (Recentin, AZD2171, AstraZeneca Pharmaceuticals, Wilmington, DE) is an orally available, highly potent inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases (VEGFR1-3) [1] on vascular endothelium. This molecule also inhibits signaling through c-kit, which has been implicated in the pathogenesis of certain central nervous system (CNS) tumors [2] . Preclinical models have demonstrated activity in suppression of tumor growth [3] , inhibition of brain metastases [4] , and reduction of tumor-associated edema [5] . The role of VEGF in malignant gliomas has been well-documented and vascular proliferation is incorporated into the classification of malignant astrocytic tumors [6] . VEGF blockade has been extensively studied in preclinical models of both primary CNS tumors as well as in metastatic models to the CNS [4] . Preclinical tests of cediranib in pediatric cancer showed improved activity when combined with multiple agents in some, but not all, models [7] [8] [9] .
Phase I adult clinical trials have identified once daily administration at 20-45 mg as the maximum-tolerated dose (MTD) using a 4-week dose-limiting toxicity (DLT) evaluation period, although frequent dose reductions and/or drug holidays were required [10] . In a phase II study in adults with progressive glioblastoma multiforme, treatment with cediranib resulted in radiographic response in 57 % of patients, an encouraging 6-month progression-free survival of 26 %, and a steroid-sparing effect in patients with manageable toxicity [10, 11] . While therapy was initiated at 45 mg, the majority of patients required either a dose reduction and/or drug holiday. Similar issues have been reported in other cancers treated with cediranib [12] . In a pediatric solid tumor phase I trial of cediranib, which excluded CNS tumors, the MTD was assessed over 4 weeks. The toxicities included nausea, vomiting, and fatigue occurring in the first patient and hypertension and prolonged corrected QT interval in the second patient treated at 12 mg/m 2 /day. Six additional patients demonstrated only one additional DLT (diarrhea). At 17 mg/ m 2 /day, two of four patients had DLTs with nausea and fatigue, and with the MTD pre-defined as <34 % of patients with a DLT, 12 mg/m 2 /day was declared the as the MTD. This MTD is similar to the 20 mg dose identified in some adult trials. One additional patient <12 years was accrued to the 12 mg/m 2 /day dose for PK analysis in this younger age group [13] . Toxicities between the adult and pediatric studies were similar and included fatigue, diarrhea, nausea, hypertension, headache, vomiting, and anorexia [14, 15] . An adult study of cediranib resulted in hypertension in 87 % of participants, 67 % of whom developed the hypertension within 3 days of starting cediranib. Almost 50 % of patients developed proteinuria [16] . The pharmacokinetics of cediranib appeared similar between adults and children although with significant interpatient variability. The median C max and AUC (0-inf) at the pediatric MTD of 12 mg/m 2 /day were 67 ng/mL and 900 ng h/mL, respectively. Toxicities were associated with a higher AUC. Responses have been observed in a number of adult tumor types and at a variety of doses. In pediatric solid tumor patients, two partial responses were observed, one each in Ewing's sarcoma (8 mg/m 2 /day) and synovial sarcoma (17 mg/m 2 /day) while two patients experienced minor responses (one each for synovial sarcoma and osteosarcoma). Two patients had prolonged stable disease, one lasting >14 cycles (alveolar soft part sarcoma) and one fibrolamellar hepatocellular carcinoma (8 cycles). A recent randomized phase II trial in adults with recurrent platinum-sensitive ovarian cancer demonstrated a significant improvement in progression-free survival in those treated with cediranib and olaparib versus olaparib alone [17] . In this trial, cediranib was used at 30 mg and the expected toxicities of fatigue, hypertension, and diarrhea were observed. Based on these results, a phase III trial of cediranib is now under development.
Based on the promising preclinical and early clinical results, we conducted a phase I study of cediranib in children with recurrent or progressive CNS tumors after standard therapy.
Material and methods

Patient population
Pediatric patients less than 22 years of age with recurrent, progressive, or refractory (considered residual tumor after therapy) primary CNS tumor were eligible. Patients had to be able to swallow intact tablets and present with a Karnofsky (age ≥ 16 years) or Lansky (age < 16 years) ≥60 % (70 % if compromised left ventricular ejection fraction). Patients had to have recovered from the toxic effects of prior therapy and be at least 3 weeks from chemotherapy (6 weeks for a nitrosourea), 1 week from biologic therapies with half-lives <48 h or greater than 5 half-lives for those greater than 48 h, greater than 4 weeks for limited-field radiation or >3 months for craniospinal radiation, greater than 3 months for autologous or 6 months for allogeneic stem cell transplantation, and off colony-forming growth factor(s) for at least 1 week (2 weeks for Neulasta). Patients had to be on stable or decreasing doses of corticosteroids for at least 1 week. Patients were required to have the following within 2 weeks of registration and within 7 days of start of therapy: an absolute neutrophil count ≥1000/ μL, platelets ≥75,000/μL, hemoglobin ≥8 g/dL (can be transfused), serum creatinine ≤1.5 times the upper limit of institutional normal for age (ULNFA) or GFR ≥70 mL/min/1.73 m 2 , bilirubin ≤1.5 times ULNFA, SGPT (ALT) ≤2.5 times ULNFA, urine dipstick or urinalysis with <1+ protein, albumin ≥3 g/dL and no overt renal, hepatic, cardiac, or pulmonary disease. Female patients of childbearing potential required a negative pregnancy test and could not be pregnant or breastfeeding, and both males and females of childbearing potential were required to use an accepted form of birth control. All patients or legal guardians were required to provide institutional approved consent (and assent where appropriate) to the study treatment and pharmacokinetics.
Exclusion criteria included any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would likely interfere with the study procedures or results. Patients receiving other anticancer therapy, patients with uncontrolled hypertension, those previously treated with cediranib, and those unable to return for follow-up or complete the required studies were excluded from participation. . Dose escalations were performed separately in strata I and II, and intrapatient dose escalation was not permitted. Doses could not exceed 60 mg (the maximal dose tested in adult patients). Treatment cycles were repeated every 28 days with no break between cycles. Patient diaries were used to monitor adherence.
Drug supply and administration
A modified version of the CRM [18, 19] was used to estimate the MTD with a target DLT probability of 25 %. For the planned expansion cohort, an attempt was made to have 6 of 12 patients treated at the MTD be below the age of 12. Patient evaluability was initially determined during the first 4 weeks of therapy; however, the DLT observation period was extended to the first 6 weeks of therapy part way through the trial due to concerns about delayed toxicities.
Toxicity assessment
Monitoring for cediranib-related toxicities included weekly physical examination, serum chemistries, CBCs, and urine protein over the first 8 weeks of therapy. Thyroid-stimulating hormone was monitored before each cycle, and electrocardiograms (EKGs) were performed monthly for the first two cycles and then as clinically indicated. Clinical and laboratory adverse events, except hypertension, were initially graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3 and then switched to CTCAEv4 when this became available. Blood pressure (BP) was measured twice daily for the first 2 months and then every 2 weeks or more often as clinically indicated. Age-and sexspecific normal values were used to determine whether BP was elevated [20] . An algorithm for management of cediranibrelated hypertension was used (appendix Fig 1) .
Definition of dose-limiting toxicities
Hematologic DLT was defined as a single episode of grade 4 neutropenia (ANC <500/μL) or thrombocytopenia (<50,000/ μL). Patients with grade 3 hypertension that could not be controlled by therapeutic intervention (appendix Fig 1) warranting treatment interruption of greater than 14 days were considered to have a dose-limiting toxicity. Other nonhematologic DLTs included any grade 3 or 4 toxicity related to cediranib except for grade 3 nausea and vomiting responsive primarily to non-parenteral antiemetics, grade 3 fever or infection, grade 3 diarrhea responsive to optimal use of antidiarrheals, and grade 3 or 4 hypokalemia, hypophosphatemia, or hypomagnesemia, which resolved to ≤ grade 2 by supplementation, within 7 days. DLTs also included any grade 2 nonhematological toxicity that persisted for more than 7 days and was considered sufficiently medically significant or sufficiently intolerable by patients as to warrant treatment interruption and/or dose reduction as well as proteinuria >2 g/24 h or 1-2 g/24 h that persisted for 7 days.
Pharmacokinetic methods
Serial whole blood samples (4.5 mL) were collected for steady-state pharmacokinetic assessment of cediranib on day 28 of course 1 at pre-dose and 1, 2, 4, 6, and 8 h post dosing and assayed by a validated bioanalytical method using solid phase extraction followed by reverse phase chromatography with detection by tandem mass spectroscopy, as previously described [15] . Concentration-time data were analyzed using non-compartmental pharmacokinetic techniques with nominal sampling times. The maximal observed plasma concentration was defined as C ss,max , with t max defined as the time to reach this peak concentration. The pre-dose trough concentration was defined as C ss,min . The area under the plasma concentration-time curve from time zero to the last collected sample (AUC 0-tlast ) was calculated by the trapezoidal rule. The duration of pharmacokinetic sampling window precluded estimation of apparent oral clearance or half-life.
Pharmacodynamic methods
Plasma VEGF, bFGF, endostatin, and IL8 and urine MMPs were quantified prior to course 1, once between days 7-14 of course 1 at the time of the optional MRI scan, and then at the time of each MRI scan, as well as at the discontinuation (with the exception of patient withdrawal) or completion of treatment using human immunoassays (Quantikine, R&D Systems, Minneapolis, MN). An attempt to assess circulating endothelial cell precursors was discontinued early due to poor accrual.
Tumor response assessment
Conventional standard MRI, MR diffusion, T1 permeability perfusion, and T2* perfusion studies were obtained within 2 weeks prior to registration, once between days 7-14 of course 1 (optional), and every 2-3 months (i.e., after courses 2, 4, 6, 9, and 12) thereafter. FDG-PET scans were obtained at baseline and prior to course 3 in consenting patients. The optional MRI scan in consenting patients obtained between days 7-14 after the start of cediranib was requested to evaluate dynamic contrast enhanced (DCE) sequences for early changes in perfusion of the tumor. Details of the imaging methods, definitions of response, and statistics are included in the supplemental methods file.
Statistical methods for correlative data analyses
A number of correlations of biomarkers to response and outcome were evaluated and considered exploratory. To investigate the changes of parameter values across time points, Bchange ratios^, i.e., fold changes, were used. The Bchange ratio^was calculated by dividing the marker value at the later time point by the marker value at the earlier time point. Paired Wilcoxon signed rank tests were used to test whether biomarkers changed significantly between baseline and course 1 (day [7] [8] [9] [10] [11] [12] [13] [14] , between baseline and end of course 2, and between course 1 (day 7-14) baseline and end of course 2. Additional details of the statistics are included in the supplemental method file.
Results
Patient characteristics
Thirty-six eligible patients were enrolled onto stratum I (nonEIACDs), and 12 eligible patients were enrolled onto stratum II (EIACDs), of whom 29 and 11 patients were evaluable, respectively. Of the 7 patients not evaluable for toxicity assessment in stratum I, five patients had rapid tumor progression, and two patients had early protocol withdrawal. Patient enrollment occurred between November 2006 and November 2011 and their characteristics are listed in Table 1 .
Toxicities and MTD
For stratum I, two evaluable patients were treated at 20 mg/m 2 without toxicity and the dose was escalated to 25 mg/m 2 . Two new evaluable patients were treated with no DLTs in the first 4 weeks, allowing for a further dose escalation to 32 mg/m 2 where three of three evaluable patients tolerated therapy without DLTs. At 40 mg/m 2 , one evaluable patient was originally classified as a DLT (grade 4 hemorrhage), but the toxicity on reassessment was reclassified as grade 2 and attributable to disease progression and thus did not qualify as a DLT. This patient was subsequently classified as inevaluable since the patient was taken off therapy prior to the end of the DLT evaluation period. By the time this was recognized, the dose evaluation period had been arbitrarily extended from 4 to 6 weeks based on PBTC Data Safety Monitoring Board (DSMB)'s recommendation to account for possible lateoccurring toxicities. For this reason, one patient at the 25 mg/m 2 (grade 3 transaminitis) and one patient at the 32 mg/m 2 dose level (grade 3 headache, confusion, dehydration, and vision change in the context of progressive disease in week 5 of therapy) were redefined as having had DLTs in the 5th or 6th week of therapy. Thus, the dose assessment level was dropped to 25 mg/m 2 . Three additional patients accrued at the 25 mg/m 2 dose level tolerated the drug without a DLT and so the dose was re-escalated to 32 mg/m 2 . Three additional patients at 32 mg/m 2 resulted in a single DLT (grade 2 proteinuria), and based on the CRM model, this dose was declared as the MTD. Per protocol, accrual was expanded at the MTD level of 32 mg/m 2 by enrolling six more patients to better define the tolerability of cediranib. Of six additional patients, one was inevaluable and three had toxicities that would have been considered DLTs had this occurred within the DLT assessment phase of the protocol (these toxicities occurred in the expansion cohort after the MTD had already been declared to be 32 mg/m 2 ). Hence, based on the combined results from the initial dose escalation and the expansion phase where 5/11 patients experienced toxicities, the 32 mg/ m 2 /day dose level was considered too toxic to be recommended as a phase II dose.
The first two patients on stratum 2 treated at 15 mg/m 2 tolerated therapy without difficulty and dose escalation proceeded to 20 mg/m 2 . While the first patient tolerated the therapy, the second and third patients treated at 20 mg/m 2 were classified as having had DLTs although both had significant confounding factors. The first patient had grade 2 intolerable diarrhea without proper loperamide prophylaxis (as required). The second patient had proteinuria and had just completed bevacizumab, an expected toxicity of this drug, placing the attribution of the toxicity in question. A decision to count both of these as DLTs but decrease their weight in the CRM model by 40 % was made by the PBTC toxicity monitoring committee. Two additional patients were therefore treated and tolerated the 20 mg/m 2 dose level. Upon reviewing the toxicities for the entire trial and taking into account the toxicities observed during the expansion phase at the initial estimate of the MTD of 32 mg/m 2 , this dose was not considered sustainable without dose reductions or drug holidays (which were not allowed in this trial). A similar excessive toxicity pattern has been observed in adults at the equivalent of 32 mg/m 2 , and in consultation with the sponsor and CTEP, the study opted to focus on evaluating the safety of 20 mg/m 2 in children. Accrual at this dose level was restarted with a goal of enrolling 12 evaluable patients in stratum I. Of the 12 patients enrolled in stratum I, 3 had DLTs (grade 2 palmar-plantar erythrodysesthesia syndrome, grade 2 CNS hemorrhage and grade 3 reversible posterior leukoencephalopathy). In stratum 2, of 9 evaluable patients enrolled at the 20 mg/m 2 dose, a grade 4 transaminitis elevation and the two 60 % weighted toxicities discussed above were identified. A summary of all DLTs observed in each stratum is provided in Table 2 . Table 3 provides a list of all toxicities observed during the trial in both strata.
Toxicities associated with cediranib included hypertension in 37 of 48 (77 %) eligible patients, 10 of whom reached grade 3 and required multiagent antihypertensive therapy (Table 3  and Supplemental Table) . Hypothyroidism was seen in 15 (31 %) patients and proteinuria in 20 (42 %) patients (two of which were considered DLTs; one each in stratum I and stratum II). Thirty-two patients had diarrhea, all but 2 were grade 1 or 2, and in one of the 2 patients with grade 3 diarrhea, this was associated with sub-therapeutic loperamide use (and was considered a DLT). Fatigue was reported in 16 patients (1 of whom was considered a DLT) while palmar-plantar erythrodysesthesia syndrome was reported in 7 patients (1 considered a DLT). Two episodes of reversible posterior leukoencephalopathy syndrome (RPLS) were reported in the same patient, one of which was considered a DLT. These are similar to the side effects observed in multiple other trials with this compound. No left ventricular dysfunction was identified in any of the patients, a finding which differs from the solid tumor pediatric phase I where these abnormalities occurred in 5 of 16 patients [13] . Effect on bone growth was assessed, and no bone-related AEs were identified although this may be influenced by the short duration of drug exposure in the majority of patients. One patient was noted to have widening of the distal femoral growth plate of unclear significance.
Pharmacokinetics
Plasma samples for cediranib pharmacokinetic studies were collected from 11 consenting patients with a median age of 11.8 (range 5.4-21.6) including eight at the 20 mg/m 2 level.
The day 28 median (range) C ss,max was 48.0 ng/mL (14.8 to 311 ng/mL), and t max was measured at between 2 and 6 h post dosing (overall median 4 h). The median (range) C ss,min at 20 mg/m 2 QD was 11.5 ng/mL (2.67 to 96.4 ng/mL). Figure 1 shows the average day 28 concentration-time profile for patients studied after receiving 20 mg/m 2 QD. The median AUC 0-tlast for this regimen was 239 ng/mL h (range 94.0 to 1870 ng/mL h), and no age dependency in AUC 0-tlast was observed in these eight patients. For comparison, the 32 mg/ m 2 QD regimen steady-state AUC 0-tlast was 892 ng/mL h (range 522 to 1260 ng/mL h; n = 2), and 770 ng/mL h (n = 1) for the 40 mg/m 2 QD regimen. No formal statistical analysis was performed to evaluate dose proportionality of the cediranib exposure because of inadequate numbers of patients with PK data treated at the different dosages.
Pharmacodynamics
In the combined cohort (both strata, all dose levels), significant increases between course 1 day 7-14 values and baseline were observed for PIGF (median fold change = 1.32, p < 0.0001), TSP (median fold change = 1.11, p = 0.0466), and VEGF (median fold change = 1.09, p = 0.0258), whereas significant decreases were noted for Tek Tie receptor (median fold change = 0.97, p = 0.04) and MMP 2 (median fold (16) 6(4) 9 (7) 26 (13) 34 (17) Platelet count decreased 22 (17) 23 (17) 3 (3) 3 (3) 25 (18) 26 (18) Lymphocyte count decreased 11 (8) 13 (10) 7(5) 12 (8) 5 (3) 5 (3) 1 (1) 1 (1) 24 (10) 31 (13) Hypothyroidism 10(10) 10(10) 10(10) 10 (10) 1 (1) 1 (1) 21 (15) 21 (15) Neutrophil count decreased 11 (8) 13 (8) 7 (4) 8 (5) 2 (2) 2 (2) 20 (10) 23 (11) Nausea 15(10) 18 (13) 3 (3) 4 (4) 1 (1) 3 (3) 19 (10) 25 (16) Fatigue 7 (7) 11 (10) 9(9) 10 (10) 2(2) 4 (4) 18 (16) 25(20) White blood cell decreased 13 (11) 17 (14) 4 (2) 5 (3) 1 (1) 1 (1) 18 (11) 23 (14) Hypocalcemia 16 (8) 23 (14) 1 (1) 3 (3) 17 (8) 26 (16) Palmar-plantar erythrodysesthesia syndrome 4(4) 4(4) 10 (7) 10 (7) 3 (3) 3 (3) 17 (7) 17 (7) Hypokalemia 14(11) 20 (16) 2 (1) 3 (2) 16 (12) 23 (18) Hypophosphatemia 10 (8) 15 (12) 4(2) 6 (4) 14 (8) 21 (13) Blood bilirubin increased 13 (7) 17 (10) 1 (1) 13 (7) 18 ( Pain in extremity 3 (3) 6 (5) 1 (1) 3 (3) 4 (4) 9 (7) Dehydration 1 (1) 2 (2) 1 (1) 2(2) 2 (2) 4 (4) 4 (4) 8 (7) Intracranial hemorrhage 4 (4) 4 (4) 4 (4) (1) 1 (1) 1 (1) 2 (2) 2 (2) 3 (3) Stomach pain 2 (2) 3 (3) 2 (2) 3 (3) Gastrointestinal disorders-other, specify 1 (1) 1 (1) 1 (1) 1 (1) 2 (2) 2(2) Hyperthyroidism 2 (2) 2 (2) 2 (2) 2 (2) Investigations-other, specify 2(2) 2 (2) 2 (2) 2(2) Lipase increased 1 (1) 1 (1) 1 (1) 1 (1) 2 (1) 2 (1) Rash acneiform 2 (2) 2 (2) 2 (2) 2 (2) Reversible posterior leukoencephalopathy syndrome 1 (1) 1 (1) 1 (1) 1 (1) 2 (1) 2 (1) Vascular disorders-other, specify 2 (2) 2 (2) 2 (2) 2 (2) Voice alteration 2 (2) 2 (2) 2 (2) 2 (2) Acidosis 1 (1) 7 (5) 1 (1) 7 (5) Seizure 1 (1) 3 (3) 3 (3) 1 (1) 1(1) 7 (6) Cough 1 (1) 4 (4) 1 (1) 1 (1) 5(4) Creatinine increased 1 (1) 3 (2) 2 (2) 1 (1) 5(3) Hydrocephalus 2 (2) 1 (1) 2 (2) 1 (1) 4(3) Nervous system disorders-other, specify 2 (2) 1 (1) 1 (1) 1 (1) 1(1) 4 (4) Pain 3 (3) 1 (1) 1 (1) 1 (1) 4 (4) Peripheral motor neuropathy 1 (1) 2 (2) 2 (2) 1 (1) 4(4)
Chest wall pain 1(1)
Endocrine disorders-other, specify 1 (1) 1 (1) 1 (1) 1 (1) 2(2) Eye disorders-other, specify 1 (1) 1 (1) 1 (1) 1 (1) 2(2) Fecal incontinence 1 (1) 2 (2) 1 (1) 2(2)
Respiratory, thoracic and mediastinal disorders-other, specify 1 (1) 1 (1) 1 (1) 1 (1) 2(2) Skin and subcutaneous tissue disorders-other, specify 1 (1) 1 (1) 1 (1) 1 (1) 2(2) Skin ulceration 1 (1) 2 (2) 1 (1) 2(2) Urinary frequency 1 (1) 2 (2) 1 (1) 2(2) Anal mucositis 1 (1) 1 (1) 1 (1) 1 (1) Anal pain 1 (1) 1 (1) 1 (1) 1(1)
Capillary leak syndrome 1(1) 1 (1) 1 (1) 1 (1) Cardiac troponin I increased 1(1) 1 (1) 1 (1) 1 (1) Cholesterol high 1(1) 1 (1) 1 (1) 1 (1) Chronic kidney disease 1(1) 1 (1) 1 (1) 1 (1) Dry mouth 1 (1) 1 (1) 1 (1) 1 (1) Dry skin 1 (1) 1 (1) 1 (1) 1 (1) Edema face 1 (1) 1 (1) 1 (1) 1 (1) Enterocolitis 1 (1) 1 (1) 1 (1) 1 (1) change = 0.95, p = 0.0129). In contrast, when we compared fold changes between course 2 day 28 values and baseline, the only significant change was observed for PIGF (median fold change = 1.54, p < 0.0034). When fold changes were compared between end of course 2 values and course 1 day 7-14, the only significant change was observed for VEGF (median fold change = 1.12, p < 0.0313). See supplemental data. No significant changes in MMP-9, MMP-9 Dimers, or MMP-9/ NGAL were observed between baseline and day 7-14 of cycle 1 or between baseline and end of cycle 2.
Tumor response
Two partial responses with greater than 50 % reduction in tumor volume and maintained for at least 6 weeks were observed in a patient with choroid plexus carcinoma (observed in course 4 and maintained for 13 courses- Fig. 2a ) and pontine glioma (observed after course 2 and maintained after course 4- Fig. 2b ). An additional patient with a recurrent high-grade glioma who initiated therapy after a gross total resection completed 2 years of cediranib in continuous CR.
Correlation between biomarkers, imaging, and PFS
There was an association of the imaging variables of tumor volume on FLAIR and PFS (HR 0.628, p value = 0.003) as well as two and three dimensional mean permeability values and PFS (HR 3.341, p = 0.0458 and HR 2.907, p = 0.0240, respectively) between day 7-14 compared to the baseline suggesting that larger tumor volumes and permeability values were associated with shorter PFS. A decrease in the diffusion ratio between baseline and course 1 day 7-14 was detected (median fold change = 0.8668, p = 0.0107). No significant associations were found between the biomarkers and MRI parameters at baseline. Negative significant associations were detected between TSP levels and FLAIR volume (r = −0.53, p = 0.0187, Fig. 3a) as well as between TSP and enhancing volume (r = −0.68, p = 0.0021, Fig. 3b ) for the fold changes between baseline and course 1 day 7-14. These findings suggest that as FLAIR volume or enhancing volume increases between baseline and course 1 day 7-14, the TSP value tends to decrease and vice versa. A significant negative association was also detected between PIGF and enhancing volume (r = −0.64, p = 0.0388, Fig. 3c ) for the fold change between baseline and end of course 2. See supplemental data. The change in the two-dimensional mean permeability values was significant (p = 0.0469) between baseline and course 1 day 7-14 and suggested a decrease from baseline. GGT increased 1(1) 1(1) 1(1) 1(1)
Pericardial effusion 1 (1) 1 (1) 1 (1) 1 (1) Pleural effusion 1 (1) 1 (1) 1 (1) 1 (1) Rectal pain 1 (1) 1 (1) 1 (1) 1 (1) Renal and urinary disorders-other, specify 1 (1) 1 (1) 1 (1) 1 (1) Serum amylase increased 1 (1) 1 (1) 1 (1) 1 (1) Cells contain the number of events (number of patients) sorted in order of decreasing frequency of the total number of toxicities There were also significant changes in the values of 2D permeability (p = 0.0078) and 3D permeability values (p = 0.0078) between baseline and end of course 2 both of which suggested a decrease from baseline. For PET imaging, no significant associations of baseline PET uptake with PFS were detected. The Spearman rank correlation showed that there was positive association of tumor vs. white matter (TM/WM) with uniformity at baseline (r = 0.43, p = 0.0312). Further Wilcoxon rank sum test suggested a statistically significant difference in tumor vs. gray matter (TM/GM) ratios among levels of uniformity at baseline (p = 0.0420). More specifically, the TM/GM uptake in the tumors with low uniformity (0 and 1 combined) was significantly less than that of uniformity 2 (p = 0.0424) and uniformity 3 (p = 0.0067), respectively. We also observed statistically significant associations between tumor PET uptake with diffusion ratio and perfusion ratio at baseline. There was a negative association between TM/WM and diffusion ratio (r = −0.53, p = 0.0086) as well as between TM/GM and diffusion ratio (r = −0.50, p = 0.0158) and a positive association between TM/WM and perfusion ratio (r = 0.60, p = 0.0246).
Discussion
The maximum-tolerated dose of daily, oral, continuously administered cediranib was initially identified to be 32 mg/m 2 in pediatric patients with CNS tumors not receiving EIACDs (an MTD was not achieved for patients receiving EIACD), although this dose is not considered the recommended dose based on excessive toxicities observed in patients treated as part of the expansion cohort at this MTD. The doses studied in this trial for both strata are similar to the MTD in adults but exceed the MTD identified for pediatric solid tumor patients which was 12 mg/m 2 /dose, orally, daily, on a continuous administration schedule. The toxicity profile identified in this study was similar to both pediatric and adult patients and included elevated blood pressure, proteinuria, fatigue, GI toxicity (diarrhea, nausea, vomiting, anorexia, abdominal pain), and elevated thyroid-stimulating hormone. Growth plate volume was increased in one patient receiving multiple treatment cycles. Cardiovascular toxicity, in particular elevated blood pressure, is thought to be an on-target effect of VEGF inhibition and was identified at all dose levels in 37 of the 48 patients but was not more evident at the higher dose levels. Similar to the pediatric phase I solid tumor study of cediranib, we utilized a hypertension management algorithm for elevation in either diastolic and/or systolic BP. No dose-limiting decreases in left ventricular function were observed, which contrasts with the pediatric solid tumor phase I trial where this was a significant finding and may be related to the use of anthracylines and chest radiation therapy in that population.
Pharmacokinetic data from two adult trials reported that the time to maximum cediranib concentrations are achieved between 1 to 8 h after oral administration, and concentrations declined with a terminal phase half-life of 12.5 to 35.4 h [14, 15] . The time to maximum cediranib concentrations observed in the present study was similar to that reported in the adult trial, although because of study design, the terminal half-life could not be calculated. The results of the present study revealed that, when treated at 20 mg/m 2 /day, the median steady-state cediranib systemic exposure in children and adolescents with CNS tumors (239 ng/mL h) is similar to that observed in adults treated with a 5-mg flat dose (226 ng/mL h) [15] . Based on this information, children and adolescents may be less susceptible to the pharmacologic effect (e.g., toxicity and antitumor effect) than adults due to the lower exposure achieved at equivalent doses.
Radiographic assessment was performed using standard MR, diffusion, and perfusion techniques. There was an association of tumor FLAIR volumes and permeability values with PFS with larger tumors and higher permeability values associated with shorter progression-free survival. There was a significant decrease in Kps values and diffusion values between baseline and course 1 day 7-14 which correlated with the drug mechanism of action and was previously described in the adult cediranib trial [11, 21] and in other antiangiogenesis pediatric clinical trials [22] [23] [24] . Larger tumors demonstrated increased permeability in our study.
PET variables were not associated with PFS. Intensity of FDG-PET tumor uptake correlated with the percentage of the tumor (as delineated on the FLAIR MR) demonstrating FDG uptake. Increased uptake in the tumors was associated with decreased diffusion values and lower cellularity. This association has been described in previous work [25] in children with brain stem glioma and in adult brain tumor patients [26, 27] . Higher PET uptake is likely associated with a greater number of viable tumor cells with increased cellularity. There was a significant correlation of PET uptake with perfusion values as assessed on T2* perfusion images. A recent study in children also noted this association likely related to a similar mechanism of radiotracer uptake and association with tumor grade [28] .
In spite of the defined role of VEGF in malignant gliomas, assessment of this marker has not correlated to activity, response, or outcome in a number of targeted VEGF therapy trials. Biomarker analysis in this study was designed to mimic those in the adult malignant glioma trial of cediranib [10, 11] . Differences in results between the studies may have resulted from a number of factors such as differences between adult and pediatric patients and the heterogeneous pediatric population being studied in this protocol compared to the more uniform GBM patient population on which results were previously reported [10, 11] . It is of interest that elevated thrombospondin levels, which when elevated, have correlated with improved response to anti-angiogenic therapies [29] [30] [31] [32] [33] , were also identified in this group of patients.
The design of this clinical trial raises a number of important issues in the identification of appropriate doses that are tolerated and suitable for both phase II studies as single agents as well as in combination with other therapies. The recognition of lateoccurring toxicities is an important factor in the determination of the tolerable dose level for clinical study. While a 4-week DLT evaluation period has been used in the majority of clinical studies, including both the adult and pediatric trials of cediranib, the extended assessment period in this study documented the additional toxicity that would have made a dose level intolerable in the intermediate term. This suggests that either a lower dose of drug is needed for development in phase II efficacy trials, or a dose reduction schema is required from the outset. Dose reduction and drug holidays have been routinely used in adults receiving cediranib. The optimum biologic effect of a drug may well be impacted by these factors, and it remains unknown what the required schedule and dosing of cediranib is. This study highlights the critical importance of the phase I trial design in achieving a useful determination of the phase II dose and the toxicity profile associated with its use. Since each of the three studies of cediranib (adult brain tumor, pediatric solid tumor, and the current study) used different toxicity assessment periods, different toxicity thresholds, and different toxicity grading systems, the identification of different MTDs is not surprising. Mandating uniformity in such cases will be important in future studies of experimental agents, especially biologic targeted drugs where classic myelosuppression is not the expected major toxicity.
The CRM model was used in this study over the more standard 3 + 3 design (used for both the adult and pediatric solid tumor phase I studies) with the goal of reducing the periods of study closure due to toxicity assessment. While for oral medications, discrete pill sizes could introduce significant variability from the target dose based on the per meter squared calculation which could have been adjusted for by the CRM method; the availability of 2.5 mg tablets and requirement that all patients be old enough to swallow pills negated the need to account for this design parameter in this trial. For pediatric clinical trials where small-dose forms are not available, these issues may be of much greater importance. The adult brain tumor, pediatric solid tumor, and current study all arrived at different declared MTDs for cediranib. Such differences in the estimated MTD are not necessarily uncommon and could arise from a variety of reasons including differences in patient populations studied as well as reliance on small sample sizes to estimate the MTD. Further, it is well known that different designs used for dose escalation can also influence the chosen MTD [34] . The definition of the MTD was also different between our study and the pediatric solid tumor study. In our study, <25 % was the targeted toxicity level for the MTD in the CRM. Later, when the safety of the 20 mg/m 2 dose was being studied, a threshold of no more than 2 DLTs in 12 patients was set as the acceptable toxicity boundary. In contrast, in the pediatric solid tumor study, 3 of 8 patients or 37 % with a DLT was considered as the MTD. The evaluation period of 6 rather than 4 weeks and the transition from CTCAE3.0 to CTCAE4.0 part way through the trial also likely impacted the MTD estimate. The determination of acceptable toxicity (definitions of what was considered a DLT) also differed between the studies, as did the ability to have dose holidays or reductions. A final factor that might influence the toxicity assessment in this report was age of the patients. In stratum 1, 8 DLTs were identified in 24 children ≥10 years old while only 1 in the 12 children <10 years of age had a DLT.
Although the single agent activity of anti-angiogenic agents appears to be less than what was initially predicted based on animal models, very few biologic or traditional chemotherapy drugs have broad single agent activity. Combination therapy has become the mainstay of effective treatment in oncology, and it appears that this will likely be true for antiangiogenic drugs as well. The encouraging results of a recent phase II randomized trial of a combination, including cediranib [17] , reflect that of other VEGF inhibitors [35] .
In summary, cediranib at 32 mg/m 2 /d daily was initially declared as the MTD for children and adolescents with CNS tumors not on EIACD. Expansion at this dose indicated that treatment at this dose level was not tolerated in a sufficient number of patients without permitting drug holidays or dose reduction. In response, additional patients were treated at 20 mg/m 2 in an effort to study the safety of this dose; however, 3 out of 11 patients treated at this dose level experienced toxicities which exceeded the pre-set safety threshold. An MTD was not achieved for the cohort on EIACD, and the maximum dose tested was 20 mg/m 2 /d. Objective responses were observed.
